Clinical Trial

Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a open label Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of NLG802, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme, in combination with temozolomide chemotherapy in children with primary brain tumors.
Trial Details
NCT Number NCT07732413
Lead Sponsor Lumos Pharma
Conditions Progressive Pediatric Brain Cancer
Enrollment 30 participants
Start Date 2026-10-08
Primary Completion 2030-10-08 (estimated)
Study Completion 2030-10-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-28